Financial Data and Key Metrics Changes - For the full year 2025, RenovoRx generated over $1 million in revenue, with fourth quarter revenues at $238,000, reflecting strong initial adoption of RenovoCath [6][20] - Gross profit for Q4 was $210,000, resulting in a gross margin of 88% [21] - Research and development expenses for Q4 were $1.5 million, totaling $6.3 million for the year, indicating continued investment in clinical trials [21] - Selling, general, and administrative expenses for Q4 were $2.2 million, with a total of $7 million for the year, reflecting disciplined cost management [21] Business Line Data and Key Metrics Changes - The company exited Q4 with nine active commercial centers, with three becoming active in the last two weeks of the year [7] - As of February 27, 2026, 12 U.S. cancer centers are utilizing RenovoCath, with 21 additional centers evaluating the device, representing a tripling of the near-term pipeline compared to Q1 2025 [9] Market Data and Key Metrics Changes - The company expects to target approximately 36 active commercial sites by year-end 2026, tripling the current footprint of 12 [10][24] - The growth in active commercial sites is expected to drive revenue growth, with a projected revenue range of $3 million to $4 million for 2026 [25] Company Strategy and Development Direction - RenovoRx is focused on scaling its commercial operations and expanding its active site network, supported by a robust pipeline of centers [10][24] - The company aims to deepen utilization at existing sites while expanding its commercial footprint, which is expected to be the primary driver of revenue growth [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial viability of RenovoCath, highlighting strong physician demand and ongoing clinical validation through the TIGeR-PaC trial [10][15] - The company is optimistic about the momentum generated in early 2026, with expectations for Q1 to be the strongest revenue quarter yet [23][24] Other Important Information - The company closed an oversubscribed private placement on March 23, 2026, resulting in gross proceeds of approximately $10 million, providing financial flexibility for commercial scale-up [22] - The TIGeR-PaC trial is on track, with 104 patients randomized as of March 24, 2026, and final data anticipated in 2027 [16] Q&A Session Summary Question: Transitioning TIGeR-PaC centers to commercial customers - Management indicated that transitioning existing TIGeR-PaC centers to commercial customers is simpler due to established familiarity and training, with most centers already having pricing agreements in place [29] Question: Catheter outlook and revenue expectations - Management refrained from providing specific guidance but indicated strong growth potential in Q1 based on early 2026 site activity and orders [33][35] Question: Clarification on active centers - Management clarified that 12 centers are currently active, with 21 additional centers in the approval process, and emphasized the importance of completing enrollment in the TIGeR-PaC trial for future commercial activity [41][52] Question: G&A expenses outlook - Management expects G&A expenses to remain around $2.2 million for Q4, with slight increases as additional sales personnel are added [42][44]

Financial Data and Key Metrics Changes - For the full year 2025, RenovoRx generated over $1 million in revenue, with fourth quarter revenues at $238,000, reflecting initial adoption of RenovoCath [6][20] - Gross profit for Q4 was $210,000, resulting in a gross margin of 88% [21] - Research and development expenses for Q4 were $1.5 million, totaling $6.3 million for the year, indicating continued investment in clinical trials [21] - Selling, general, and administrative expenses for Q4 were $2.2 million, with a total of $7 million for the year, reflecting disciplined cost management [21] Business Line Data and Key Metrics Changes - The company exited Q4 with nine active commercial centers, with three becoming active in the last two weeks of the year [7] - As of February 27, 2026, 12 U.S. cancer centers are utilizing RenovoCath, with 21 additional centers evaluating the device, representing a tripling of the near-term pipeline compared to Q1 2025 [9] Market Data and Key Metrics Changes - The company is targeting approximately 36 active commercial sites by year-end 2026, tripling the current footprint of 12 [10][24] - The growth in active commercial sites is expected to drive revenue growth, with a projected revenue range of $3 million to $4 million for 2026 [25] Company Strategy and Development Direction - RenovoRx is focused on scaling its commercial operations and expanding its network of active commercial cancer center clients [10][11] - The company aims to deepen utilization at existing sites while expanding its commercial footprint, supported by a robust pipeline of centers [10][11] - The transition of TIGeR-PaC trial centers to commercial customers is seen as a key strategy for growth [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial viability of RenovoCath, citing strong physician demand and ongoing clinical evidence supporting its effectiveness [10][15] - The company is optimistic about achieving significant revenue growth in 2026, driven by new site activations and increased orders [23][25] Other Important Information - The company closed an oversubscribed private placement on March 23, 2026, resulting in gross proceeds of approximately $10 million, providing financial flexibility for scaling operations [22] - The TIGeR-PaC trial is on track, with 104 patients randomized as of March 24, 2026, and final data anticipated in 2027 [16] Q&A Session Summary Question: Transitioning TIGeR-PaC centers to commercial customers - Management indicated that transitioning is simpler due to existing familiarity and training of physicians, with most centers already having pricing agreements in place [29] Question: Catheter outlook and revenue expectations - Management refrained from providing specific revenue guidance but expressed confidence in significant growth over Q4 based on early 2026 activity [33][35] Question: Active centers and revenue generation - Management clarified that 12 centers are currently active, with 21 more in the approval process, and emphasized the importance of converting trial centers to commercial use [41][51] Question: G&A expenses and future projections - Management expects G&A expenses to remain around $2.2 million per quarter, with slight increases as additional sales personnel are added [42][44]

Financial Data and Key Metrics Changes - For the full year 2025, RenovoRx generated over $1 million in revenue, with Q4 revenues at $238,000, reflecting strong initial adoption of RenovoCath [6][21] - Gross profit for Q4 was $210,000, resulting in a gross margin of 88% [22] - Research and development expenses for Q4 were $1.5 million, totaling $6.3 million for the year, indicating continued investment in clinical trials [22] - Selling, general, and administrative expenses for Q4 were $2.2 million, with a total of $7 million for the year, reflecting disciplined cost management [22] Business Line Data and Key Metrics Changes - The company exited Q4 with nine active commercial centers, with three becoming active in the last two weeks of the year [6][7] - As of February 27, 2026, 12 U.S. cancer centers are utilizing RenovoCath, with 21 additional centers evaluating the device, representing a tripling of the near-term pipeline compared to Q1 2025 [10] Market Data and Key Metrics Changes - The company is targeting approximately 36 active commercial sites by year-end 2026, tripling its current footprint of 12 [11][25] - The growth of active commercial site networks is expected to drive revenue growth, with a projected revenue range of $3 million to $4 million for 2026 [26] Company Strategy and Development Direction - The company is focused on scaling its commercial operations and expanding its active site network, supported by a robust pipeline of centers [11][12] - The transition of TIGeR-PaC trial sites to commercial use is seen as a critical step in driving revenue growth [9][52] - The company aims to leverage clinical data to build physician confidence and drive adoption of RenovoCath [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial potential of RenovoCath, citing strong physician demand and a validated commercial model [11][19] - The company anticipates Q1 2026 to be the strongest revenue quarter yet, with significant growth expected throughout the year [24][25] - Management emphasized the importance of disciplined growth and capital efficiency in scaling operations [13][22] Other Important Information - The company closed an oversubscribed private placement on March 23, 2026, resulting in gross proceeds of approximately $10 million, providing financial flexibility for growth initiatives [23][24] - The TIGeR-PaC trial is on track for completion by mid-2026, with positive data expected to be transformative for the business [18][19] Q&A Session Summary Question: Transitioning TIGeR-PaC centers to commercial customers - Management indicated that transitioning existing trial centers to commercial use is simpler due to established familiarity and training, with most centers already having pricing agreements in place [29][30] Question: Catheter outlook and revenue expectations - Management refrained from providing specific revenue guidance but indicated strong confidence in Q1 performance based on early 2026 activity [34][36] Question: Active centers and revenue growth drivers - Management clarified that growth is driven by both new centers and increased usage at existing centers, with a focus on expanding the active site network [36][38] Question: Sales and marketing personnel adequacy - Management confirmed that the current sales team is sufficient to reach the target of 36 active centers, with plans to add more personnel as needed [63]

Core Insights - RenovoRx generated $1.1 million in revenue from RenovoCath in its first full year of commercialization, indicating strong initial adoption by physicians and demand in active cancer centers [2][3][15] - The company has established a solid commercial infrastructure and plans to scale operations in 2026, focusing on high-volume cancer centers [2][10] - The ongoing Phase III TIGeR-PaC trial is on track for full enrollment by mid-2026, with final data expected in 2027 [1][7][8] Financial Performance - For the year ended December 31, 2025, RenovoRx reported revenue of $1.1 million, a significant increase from $43,000 in 2024 [15][25] - The net loss for 2025 was approximately $11.2 million, compared to $8.8 million in the previous year [19][25] - Cash and cash equivalents were approximately $7.0 million as of December 31, 2025, and increased to $13 million following a private placement in March 2026 [16][14] Commercialization and Market Strategy - As of early 2026, 12 cancer centers are actively using RenovoCath, with an additional 21 centers evaluating or preparing for activation, tripling the near-term pipeline compared to early 2025 [2][5] - The company estimates a total addressable market (TAM) of approximately $400 million for RenovoCath as a stand-alone device, with potential for multi-billion-dollar expansion into additional solid tumor indications [6][29] - The company is observing repeat ordering patterns and increased procedural utilization, reinforcing confidence in physician satisfaction and the potential for recurring revenue [5][4] Clinical Development - The TIGeR-PaC trial is evaluating intra-arterial delivery of gemcitabine via RenovoCath for locally advanced pancreatic cancer, with 104 patients randomized as of March 24, 2026 [7][8] - The trial has reached a key milestone with the completion of a second interim analysis, and the independent Data Monitoring Committee recommended continuing the study without modification [8][9] - The company aims to transition 17 cancer centers involved in the TIGeR-PaC trial to commercial customers for RenovoCath in the second half of 2026 [2][7] Leadership and Advisory Board - In February 2026, RenovoRx strengthened its executive leadership team with the appointment of Mark Voll as Chief Financial Officer, bringing over 30 years of financial leadership experience [11] - The company established the RenovoCath Medical Advisory Board to provide strategic clinical guidance, comprising leading interventional oncology experts [12]

Core Viewpoint - RenovoRx, Inc. has successfully closed an oversubscribed private placement, raising approximately $10 million to support its business plan and clinical milestones, particularly for its FDA-cleared drug-delivery device, RenovoCath [1][3][6] Financing Details - The private placement was led by both new and existing institutional investors, including Transcend Partners, LLC and AIGH Capital Management LLC, with participation from RenovoRx's senior management and Board of Directors [2] - A total of 10,638,790 shares of common stock were issued at a price of $0.938 per share, along with revenue milestone warrants for an additional 5,319,392 shares [4] - The exercise price for the revenue milestone warrants is set at $1.751, representing a 100% premium to the offering price [5] Business Strategy and Milestones - The proceeds from the financing will be utilized to accelerate the market adoption of RenovoCath and advance clinical development, with a focus on achieving full enrollment in the pivotal Phase III trial by mid-2026 [3][7] - The company anticipates significant growth in commercial revenues, which will help reduce cash burn and support the goal of cash-flow breakeven operations [3] Leadership and Team - Mark Voll has been appointed as Chief Financial Officer, bringing a strong track record of scaling public companies [3] - The company has established a core, nimble, and capital-efficient commercial team for RenovoCath [3] Clinical Development - RenovoRx is nearing completion of enrollment in its pivotal Phase III TIGeR-PaC clinical trial, with results expected in 2027 [3][7] - The trial involves 16 additional commercial centers that are already trained on RenovoCath procedures and have begun purchasing devices [3] Product Overview - RenovoCath is designed for targeted delivery of fluids to specific sites in the peripheral vascular system and is indicated for temporary vessel occlusion [10][11] - The company is also evaluating a novel drug-device combination product candidate, intra-arterial gemcitabine delivered via RenovoCath, in the ongoing Phase III trial [13][14]

Core Viewpoint - RenovoRx, Inc. is set to announce its fourth quarter and full year 2025 financial results and business highlights on March 30, 2026, showcasing its progress in oncology therapies and the commercialization of its FDA-cleared drug-delivery device, RenovoCath [1][4]. Group 1: Financial Results and Conference Call - The conference call will take place on March 30, 2026, at 4:30 p.m. ET, where management will discuss financial results and business highlights [1][4]. - A recording of the call will be available on the Investor Relations website, with a dial-in replay accessible until April 13, 2026 [4]. Group 2: Clinical Pipeline and Product Development - Management will provide updates on the clinical pipeline, particularly the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, which is on track for enrollment completion in the first half of 2026, with final data expected in 2027 [3]. - The company is focusing on generating new data through post-marketing registry studies and supporting investigator-initiated trials (IIT) in pancreatic cancer, which are designed to be cost-neutral and provide meaningful data for the TAMP™ therapy platform [3]. Group 3: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and RenovoCath, having received its first commercial purchase orders in December 2024, generating approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025 [6]. - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [6]. Group 4: Product Candidates and Regulatory Status - RenovoRx is evaluating its intra-arterial gemcitabine product candidate delivered via RenovoCath in the ongoing Phase III TIGeR-PaC trial, which is regulated under a U.S. investigational new drug application [7]. - The IAG combination product candidate has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8].

Core Viewpoint - RenovoRx, Inc. has successfully executed an oversubscribed private placement expected to generate approximately $10 million in gross proceeds, aimed at accelerating its commercialization efforts and advancing clinical trials for its innovative oncology therapies [1][3][6] Financing Details - The financing is led by prominent life-science institutional investors, with participation from the company's senior management and board members [2] - The private placement will involve the issuance of approximately 10,638,869 shares of common stock at a purchase price of $0.938 per share, along with milestone-based warrants for an additional 5,319,434 shares [4][5] Use of Proceeds - Proceeds from the financing are intended to support RenovoRx's commercialization of RenovoCath and to advance the pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer, targeting full enrollment by mid-2026 [3][12] - The company aims to achieve cash-flow breakeven operations while reducing cash burn and increasing revenue [3] Warrant Details - The milestone warrants have an exercise price of $1.751 per share, representing a 100% premium to the common stock offering price, and are exercisable immediately [5] - The warrants will expire either 30 days after the company announces achieving $1.5 million in gross product revenue or on March 30, 2029 [5] Company Overview - RenovoRx is focused on developing targeted oncology therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device designed for localized treatment [11][12] - The company has generated approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025, with repeat orders from several customers [12]

Core Insights - RenovoRx has significantly increased its commercial presence, with 12 U.S. cancer centers now utilizing the RenovoCath device, and a total of 33 centers requesting access, tripling the potential commercial centers since Q1 2025 [1][2] - The company has successfully completed over 700 RenovoCath procedures since receiving FDA clearance in 2014, indicating strong clinical adoption and physician satisfaction [1][4] - The appointment of Ramtin Agah, MD, as Executive Chairman is expected to enhance the company's commercial strategy and market penetration efforts [5][6] Commercial Progress - The number of cancer centers using RenovoCath has increased to 12, with additional centers preparing to launch, indicating a robust sales pipeline [1][2] - The company has seen a rise in repeat purchase orders from existing customers, reflecting strong demand and physician satisfaction with the RenovoCath device [3] - RenovoRx's sales and marketing team, launched in late 2025, has contributed to the growing adoption of RenovoCath, supported by real-world clinical evidence of its effectiveness [4] Financial Outlook - The company anticipates revenue expansion in 2026 due to the increasing clinical demand for RenovoCath as it integrates into cancer treatment paradigms [2] - In Q1 2025, three patients initiated treatment via the TAMP therapy across four cancer centers, with expectations of at least 10 new patients in the current year [5] - Approximately $900,000 in revenues were generated from RenovoCath sales in the first nine months of 2025, with several customers initiating repeat orders [9] Strategic Developments - The expanded role of Dr. Agah as Executive Chairman is aimed at leveraging his medical expertise to drive broader market adoption of RenovoCath [5][6] - The company is actively exploring further revenue-generating activities, either independently or in partnership with a medical device commercial partner, to meet anticipated demand [9] - RenovoRx is also evaluating its novel drug-device combination product candidate, IAG, in an ongoing Phase III trial, which could further enhance its product offerings [10][11]

Core Insights - RenovoRx, Inc. announced the acceptance of a clinical data abstract for presentation at the 2026 Society of Interventional Radiology Annual Scientific Meeting, focusing on the TAMP™ therapy platform for treating locally advanced pancreatic cancer [1][2] Company Overview - RenovoRx is a life sciences company specializing in targeted oncology therapies and has developed the RenovoCath, an FDA-cleared drug-delivery device [5] - The company aims to address high unmet medical needs in cancer treatment through innovative solutions [5] Clinical Research and Development - The abstract titled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer" explores the efficacy of local, targeted intra-arterial chemotherapy delivery using the TAMP therapy platform [2][3] - The research evaluates the role of metabolic imaging (FDG PET/CT) in assessing therapeutic activity in patients with refractory pancreatic cancer [2] Product Details - RenovoCath is designed for the isolation of blood flow and delivery of therapeutic agents directly to tumor sites, potentially improving treatment efficacy while minimizing systemic toxicity [4][5] - The device is indicated for temporary vessel occlusion and has received Orphan Drug Designation for pancreatic and bile duct cancers, granting seven years of market exclusivity upon FDA approval [8] Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices [6] - The company generated approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025, with several customers placing repeat orders [6] Ongoing Trials - The company is evaluating a novel drug-device combination product candidate, intra-arterial gemcitabine delivered via RenovoCath, in the Phase III TIGeR-PaC trial [7] - This candidate is currently under investigation and has not yet been approved for commercial sale [8]

Core Insights - RenovoRx has established a Medical Advisory Board (MAB) to enhance its TAMP™ therapy platform, focusing on clinical indications with high unmet medical needs [1][2][5] Group 1: Medical Advisory Board Formation - The MAB consists of leading US interventional radiology experts who will provide strategic clinical insights to advance the TAMP therapy platform [2][3] - The MAB will complement the existing Scientific Advisory Board, which focuses on scientific research and clinical program strategy [2] Group 2: Clinical and Market Strategy - The MAB will support ongoing clinical and market strategies and provide insights into potential investigator-initiated trials, which are designed to broaden the application of the TAMP platform [3] - Current trials supported by RenovoRx include studies on borderline resectable and metastatic pancreatic cancer, with potential for expanding targeted indications [3] Group 3: Feedback and Market Introduction - The MAB will also provide feedback to the sales and marketing team as they work to bring RenovoCath to market as a standalone device within its FDA-cleared indications [4] Group 4: RenovoCath Overview - RenovoCath is an FDA-cleared drug-delivery device intended for targeted therapeutic delivery across the arterial wall near tumor sites, aiming to minimize toxicities compared to systemic intravenous therapy [12][13] - The device is also indicated for temporary vessel occlusion in various applications, including arteriography and chemotherapeutic drug infusion [12] Group 5: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices, generating approximately $900,000 in revenue for the first nine months of 2025 [14] - The company is actively exploring further revenue-generating activities to meet anticipated demand [14] Group 6: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [15][16] - IAG has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [17]